Liver diseases related to MDR3 (ABCB4) gene deficiency

Frontiers in Bioscience

Volumn 14, Issue 11, 2009, Pages 4242-4256

  Gonzales, Emmanuel ^a,b   Davit Spraul, Anne ^a   Baussan, Christiane ^a   Buffet, Catherine ^a   Maurice, Michele ^b   Jacquemin, Emmanuel ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

ABCB4; Biliary cirrhosis; Cholestasis of pregnancy; Cholesterol gallstone; Drug induced cholestasis; LPAC; Multidrug resistance 3; Progressive familial intrahepatic cholestasis type 3; Review; Transient neonatal cholestasis; Ursodeoxycholic acid

Indexed keywords

MUS;

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 3; PHOSPHOLIPID;

ANIMAL; GENETICS; GENOTYPE; HEPATOBILIARY SYSTEM; HUMAN; LIVER DISEASE; METABOLISM; MOUSE; MOUSE MUTANT; PHENOTYPE; REVIEW;

ANIMALS; BILIARY TRACT; GENOTYPE; HUMANS; LIVER DISEASES; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS; PHENOTYPE; PHOSPHOLIPIDS;

EID: 63849239518     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3526     Document Type: Article

References (110)

1. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, hadchouel M. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 23, 904-908(1996) (Pubitemid 26112008)
2. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 117, 112-124(1969)
3. Linarelli LG, Williams CN, Phillips MJ. Byler's disease: fatal intrahepatic cholestasis. J Pediatr 81, 484-492(1972)
4. Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 18, 134-141(1994) (Pubitemid 24056469)
5. Williams CN, Kaye R, Baker L, Hurwitz R, Senior JR. Progressive familial cholestatic cirrhosis and bile acid metabolism. J Pediatr 81, 493-500(1972)
6. Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease). Eur J Pediatr 153, 424-428(1994) (Pubitemid 24183780)
7. Bull LN, Carlton VE, Stricker NL, Baharloo S, De Young JA, Freimer NB, Magid MS, Kahn E, Markowitz J, Di Carlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught pr, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KD, Agostini Jr RM, Kocoshis SA, Reyes J, Knisely AS. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity. Hepatology 26, 155-164(1997) (Pubitemid 27280320)
8. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 339, 1217-1227(1998)
9. Bezerra JA, Balistreri WF: Intrahepatic cholestasis: order out of chaos. Gastroenterology 117, 1496-1498(1999)
10. Jacquemin E, Hadchouel M: Genetic basis of progressive familial intrahepatic cholestasis. J Hepatol 31, 377-381(1999) (Pubitemid 29349769)
11. Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ulbick GA, Meier PJ. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 43, 342-357(2005) (Pubitemid 40956889)
12. Baussan C, Cresteil D, Gonzales E, Raynaud N, Dumont M, Bernard O, Hadchouel M, Jacquemin E. Genetic cholestatic liver diseases: The exemple of progressive familial intrahepatic cholestasis and related disorders. Acta Gastro-Enterologica Belgica LXVII, 179-183 (2004) (Pubitemid 38879734)
13. Bull LN, van Eijk M J T, Pawlikowska L, De Young JA, Juijn JA, Liao M, Klomp L W J, Lomri N, Berger R, Scharschmidt BR, Knisely AS, Houwen R H J, Freimer NB. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 18, 219-224(1998) (Pubitemid 28117258)
14. Klomp L W J, Vargas JC, Van Mil S W C, Pawlikowska L, Strautnieks SS, Van Eijk M J T, Juijn JA, Pabón-Peña C, Smith LB, De Young JA, Byrne JA, Gombert J, Van DerBrugge G, Berger R, Jankowska J, Villa E, Knisely AS, Thompson RJ, Freimer NB, Houwen R H J, Bull LN. Characterization of mutations in ATP8B1 Associated with hereditary cholestasis. Hepatology 40, 27-38(2004) (Pubitemid 38868920)
15. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Németh A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20, 233-238(1998) (Pubitemid 28507666)
16. Jansen P L M, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld G J E J, Koning JH, De Jager-Krikken A, Kuipers F, Stellard F, Bijleveld C M A, Gouw A, van Goor H, Thompson RJ, Muller M. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117, 1370-1379(1999)
17. Van Mil S W C, Van DerWoerd WL, Van DerBrugge G, Strum E, Jansen P L M, Bull LN, Van DenBerg I E T, Berger R, Houwen R H J, Klomp L W J. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 127, 379-384(2004) (Pubitemid 39091885)
18. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak-Ulbick GA. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 14, 91-102(2004) (Pubitemid 38253644)
19. Maggiore G, Bernard O, Riely C, Hadchouel M, Lemonnier A, Alagille D. Normal serum gamma-glutamyltranspeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis. J Pediatr 111, 251-252(1987) (Pubitemid 17122336)
20. Maggiore G, Bernard O, Hadchouel M, Lemonnier A, Alagille D. Diagnostic value of serum g-glutamyl transpeptidase activity in liver diseases in children. J Pediatr Gastroenterol Nutr 12, 21-26(1991)
21. Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 18, 128-133(1994) (Pubitemid 24056468)
22. De Vree J M L, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink R P J, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95, 282-287(1998) (Pubitemid 28103945)
23. Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, Bordo D, Coviello DA. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet, e29 (2007)
24. Ganne-Carrié N, Baussan C, Grando V, Gaudelus J, Cresteil D, Jacquemin E. Progressive familial inrahepatic cholestasis type 3 revealed by oral contraceptive pills. J Hepatol 38, 693-694(2003) (Pubitemid 36560660)
25. Keitel V, Burdelski M, Warskulat U, Kühlkamp T, Keppler D, Häussinger D, Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41, 1160-1172(2005) (Pubitemid 40593925)
26. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric an adult liver disease: One gene for three diseases. Semin Liver Dis 21, 551-562(2001) (Pubitemid 33131047)
27. Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrié N. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology. 135, 131-141(2008) (Pubitemid 351899020)
28. Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, Jeng YM, Chang MH. Progressive familial intrahepatic cholestasis with high γ- glutamyltranspeptidase levels in Taiwanese infants: Role of MDR3 gene defect? Pediatr Res 50, 50-55(2001)
29. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27, 77-98(2007)
30. Jacquemin E, de Vree J L M, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Burdelski M, PJ Bosma, Bernard O, Michelle Hadchouel M, Oude Elferink R P J. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120, 1448-1458(2001) (Pubitemid 32322319)
31. Smit JJ, Shinkel AH, Oude Elferink RP, Groen AK, Wagennar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Room MA. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451-462(1993) (Pubitemid 23335071)
32. Reutz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071-1081(1994) (Pubitemid 24208866)
33. Smit JJ, Shinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR, Borst P. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 71, 638-649(1994) (Pubitemid 24374570)
34. Smith AJ, de Vree J M L, Ottenhoff R, Elferink RP, Schinkel AH, Borst P. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidycholine excretion absent in mdr2 (-/-) mice. Hepatology 28, 530-536(1998) (Pubitemid 28363683)
35. Oude Elferink R P J, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 453, 601-10(2007) (Pubitemid 46192533)
36. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink R P J, van der Valk MA, Borst P, Offerhaus GJ. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145, 1237-1245(1994)
37. van Nieuwkerk C J M, Oude Elferink R P J, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van DenBergh Weerman MA, and Offerhaus GJ. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 p-glycoprotein gene. Gastroenterology 111, 165-171(1996) (Pubitemid 26226896)
38. Fickert P, Fuschsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangites in MDR2 (ABCB4) knockout mice. Gastroenterology 127, 261-274(2004) (Pubitemid 38962293)
39. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodesoycholic acid aggravates bile infarcts in bile duct-ligated and MDR2 knockout mice via disruption of cholangioles. Gastroenterology 123, 1238-1251(2002)
40. Pauli-Magnus C, Reinhold K, Fattinger K, Lang T, Anwald B, Kullac-Ulbick GA, Beuers U, Meier PJ. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39, 779-791(2004) (Pubitemid 38337658)
41. Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff M J H, Graf R, Clavien PA. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in MDR2 +/-mice. Hepatology 43, 1022-1031(2006) (Pubitemid 43724627)
42. Strautnieks S, Lopes A, Underhill J, Gerred S, Nibbering K, Knisely A, Portman B, Bomford A, Heaton N, Mieli-Vergani G, Oude Elferink R, O'Grady J, Wali S, Thompson R. Critical residues in the multidrug resistance 3 protein gene associated with adult onset of cholangiopathy and intrahepatic cholestasis of pregnancy. Hepatology 36, 415A (2002)
43. Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126, 1220-1222(2004)
44. Trauner M, Fickert P, Lammert F, Marschall HU. Correspondence. Gastroenterology 126, 1222-1223(2004)
45. Elferink RP, Ottenhoff R, van Marle J, Frijters CM, Smith AJ, Groen KA. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest 102, 1749-1757(1998) (Pubitemid 28516260)
46. Hamosh A, Rosenstein BJ, Cutting GR. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1, 542-544(1992)
47. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 29, 607-649(1995) (Pubitemid 26005354)
48. Beaudet L, Urbatsch IL, Gros P. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity. Biochemistry 37, 9073-9082(1998) (Pubitemid 28299680)
49. Urbatsch IL, Beaudet L, Carrier I, Gros P. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry 37, 4592-4602(1998) (Pubitemid 28217177)
50. Morita SY, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H, Matsuo M, Ueda K. Bile salt-dependant efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 46, 188-199(2007) (Pubitemid 47171936)
51. Loo TW, Clarke DM. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33, 14049-14057(1994) (Pubitemid 24382347)
52. Loo TW, Clarke DM. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J Biol Chem 272, 20986-20989(1997) (Pubitemid 27373952)
53. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S, Kuwano M. Genomic structure of the canalicular multispecific organic aniontransporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 64, 739-746(1999) (Pubitemid 30460416)
54. Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nielson-Piercy C, De Sweit M, Warnes G, Elias E, Higgins CF, Johnston DG, McCarty MI, Williamson C. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 9, 1209-1217(2000) (Pubitemid 30248607)
55. Riordan JR. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am J Hum Genet 64, 1499-1504(1999) (Pubitemid 30481502)
56. Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wildtype and mutated bile salt export pumps. Hepatology 45, 1506-1516(2007) (Pubitemid 46918335)
57. Durand-Schneider AM, Abarane A, Delautier D, Ait Slimane T, Delaunay JL, Gora S, Trugnan G, Jacquemin E, Maurice M. Effect of missense mutations of the MDR3 gene identified in patients with progressive familial intrahepatic cholestasis type III. Hepatology 44, 622A (2003)
58. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44, 62-74(2006) (Pubitemid 44049139)
59. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ulbick GA, Meier PJ, Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17, 47-60(2007) (Pubitemid 46183791)
60. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 353, 210-211(1999) (Pubitemid 29088042)
61. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97, 3473-3478(2000) (Pubitemid 30183327)
62. Forbes JR, Cox DW. Funtional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 63, 1663-1674(1998) (Pubitemid 30415729)
63. Ortiz D, Arias IM. MDR3 mutations: A glimpse into Pandora's box and the future of canalicular pathophysiology. Gastroenterology 120, 1549-1552(2001) (Pubitemid 32322331)
64. Van Mil S W C, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuck V, Moore GE, Lammert F, Glantz AG, Mattson LA, Whittaker J, Parker MG, White R, Williamson C. Heterozygous mutation of the central bile acid sensor FXR (NR1H4) predisposes ton intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507-516(2007) (Pubitemid 47187340)
65. Junc C, Driancourt C, Baussan C, Zater M, Hadchouel M, Meunier-Rotival M, Guiochon-Mantel A, Jacquemin E. Prenatal molecular diagnosis of inherited cholestatic diseases. J Pediatr Gastroenterol Nutr 44, 453-458(2007) (Pubitemid 46573228)
66. Liu C, Arorrow BJ, Jegga AG, Wang N, Miethke A, Mourya R, Bezzera JG. Novel resequensing chip customized to diagnose mutations in patients with genetic cholestasis. Gastroenterology 132, 119-126(2007) (Pubitemid 46108747)
67. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, Bernard O. Ursodeoxycholic therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25, 519-523(1997) (Pubitemid 27106425)
68. Gupta S, Stravitz T, Pandak WM, Müller M, Z. Vlahcevic R, Hylemon PB. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 32, 341-347(2000) (Pubitemid 30614666)
69. Lincke CR, Smit J J M, van Der Velde-Koerts T, Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 266, 5303-5310(1991) (Pubitemid 21909491)
70. Bacq Y, Sapey T, Bréchot MC, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a french prospective study. Hepatology 26, 358-364(1997) (Pubitemid 27328313)
71. Schneider G, Paus TC, Kullak-Ulbick GA, Meier PJ, Wienker TF, Lang T, Van de Vondel P, Sauerbruch T, Reichel C. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 45, 150-158(2007) (Pubitemid 46144374)
72. Eloranta ML, Heiskanen J T M, Hiltunen MJ, Mannermaa AJ, Punnonen K R A, Heinonen ST. Multirug resistance 3 gene mutation 1712delT and estrogen receptor alpha gene polymorphisms in Finnish women with obstetric cholestasis. Eur J Obstet Gynecoland Reprod Biol 104, 109-112(2002) (Pubitemid 36158816)
73. Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 40, e70 (2003)
74. Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet 40, e32 (2003)
75. Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, Riikonen S, Ylikorkala O, Lehesjoki AE, Williamson C, Aittomaki K. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 52, 1025-1029(2003) (Pubitemid 36765296)
76. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131, 624-9(2006) (Pubitemid 44142448)
77. Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattson LA, Marschall HU, Lammert F. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 56, 265-70(2006)
78. Eloranta ML, Hakli T, Hiltunen M, Helisami S, Punnonen K, Heinonnen S. Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand J Gastroenterol 38, 648-652(2003) (Pubitemid 36724045)
79. Holzbach RT, Sivak DA, Braun WE. Familial recurrent intrahepatic cholestasis of pregnancy: A genetic study providing evidence for transmission of a sex-limited, dominant trait. Gastroenterology 85, 175-179(1983) (Pubitemid 13106341)
80. Hooiveld G J E J, Vos TA, Scheffer GL, Van Goor H, Koning H, Bloks V, Loot AE, Meijer DK, Jannsen PL, Kuipers F, Müller M. 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117, 678-687(1999) (Pubitemid 29409255)
81. Kok T, Bloks VW, Wolters H, Havinga R, Jansen P L M, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPAR alpha)-mediated regulation of resistance 2 (MDR2) expression and function in mice. Biochem J 369, 539-547(2003) (Pubitemid 36246237)
82. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakács G, Váradi A, Sarkadi B, Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275, 23530-23539(2000) (Pubitemid 30624635)
83. Lammert F, Wang D Q H, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto-and hepatolithiasis in MDR2 +/-mice: A model for low phospholipid-associated cholelithiasis. Hepatology 39, 117-128(2004) (Pubitemid 38461474)
84. De Pagter A G F, Van Berge Henegouwen GP, Ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 71, 202-207(1976)
85. Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis. A report of 26 cases. J Clin Gastroenterol 11, 546-551(1989) (Pubitemid 19253234)
86. Mazzella G, Rizzo N, Azzarolli F, Simoni P, Bovicelli L, Miracolo A, Simonazzi G, Colecchia A, Nigro G, Mwangemi C, Festi D, Roda E. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies ans mothers. Hepatology 33, 504-508(2001) (Pubitemid 32185210)
87. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129, 894-901(2005) (Pubitemid 41242682)
88. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120, 1459-1467(2001) (Pubitemid 32322320)
89. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R. ABCB4 gene mutations associated cholelithiasis in adults. Gastroenterology 125, 452-459(2003) (Pubitemid 36929427)
90. Kano M, Shoda J, Sumazaki R, Oda K, Nimura Y, Tanaka N. Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis. Hepatology Res 29, 160-166(2004) (Pubitemid 38780132)
91. Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet Journal of Rare Diseases 2, e29 (2007)
92. Jacquemin E, Lykavieris P, Chaoui N, Hadchouel M, Bernard O. Transient neonatal cholestasis: origin and outcome. J Pediatr 133, 563-567(1998) (Pubitemid 28465388)
93. Hermezui B, Sanlaville D, Girard M, Léonard C, Lyonnet S, Jacquemin E. Heterozygous bile salt export pump deficiency: A possible genetic predisposition to transient neonatal cholestasis. J Pediatr Gastroenterol Nutr 42, 114-116(2006) (Pubitemid 43061021)
94. Bezzera J, Schneider BL. Genetic modifiers of cholestatic liver disease: an evolving field. J Pediatr Gastroenterol Nutr 42, 7-8(2006)
95. Lucena JF, Herrero JI, Quiroga J, Sangro B Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124, 1037-1042(2003) (Pubitemid 36389806)
96. Vos TA, Hooiveld G J E J, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, Müller M. Up-regulation of the multidrugresistance genes, Mrp1 and Mdr1b, and downregulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28, 1637-1644(1998) (Pubitemid 28549135)
97. Matsumoto T, Miyazaki H, Nakahashi Y, Hirohara J, Seki T, Inoue K, Okazaki K. Multidrug resistance 3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatology Res 30, 125-136(2004) (Pubitemid 39654742)
98. Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129, 735-740(2005) (Pubitemid 41102188)
99. Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40, 260-263(2007) (Pubitemid 38868945)
100. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuschbichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by Rifampicin an ursodesoxycholic acid in humans. Gastroenterology 129, 476-485(2005) (Pubitemid 41096635)
101. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid X receptor agonists GW4064 in rat models of intra-and extrahepatic cholestatis. J Clin Invest 112, 1678-1687(2003) (Pubitemid 38063725)
102. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pelliciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313, 604-612(2005) (Pubitemid 40604160)
103. Wilschanski MN, Yahav Y, Yaccov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349, 1433-1441(2003) (Pubitemid 37211058)
104. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. Cucurmin, a major constituent of turmeric corrects cystic fibrosis defects. Science 304, 600-602(2004) (Pubitemid 38541921)
105. Ananthanarayanan M. Therapy for hepatocyte transporter trafficking mutations: the time is now. Hepatology 45, 1340-1342(2007) (Pubitemid 46918316)
106. van Helvoort A, Smith JA, Sprong H, Fritzsche I, Schinkel AH, Piet Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87, 507-517(1996) (Pubitemid 26374324)
107. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 350, 711-712(1997)
108. Altschuler EL. Azithromycin, the multidrug-resistant protein and cystic fibrosis. Lancet 351, 1286(1998) (Pubitemid 28181983)
109. Lamireau T, Bouchard G, Yousef IM, Clouzeau-Girard H, Rosenbaum J, Desmouliere A, Tuchweber B. Dietary lecithin protects against cholestatics liver disease in cholic acid-fed ABCB4-deficient mice. Pediatr Res 6, 185-190(2007) (Pubitemid 46146876)
110. De Vree J M L, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink R P J. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720-1730(2000) (Pubitemid 32198697)